UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M

UroGen Pharma Ltd.

Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.
ZUSDURI net product revenue $50.4M, 73% QoQ growth; 1,444 activated sites, 452 prescribers.
JELMYTO revenue $22.0M (Q2 2026) vs $24.2M (Q2 2025); FY guidance $97-101M.
Net loss $14.4M ($0.28/share) vs $49.9M ($1.05) in Q2 2025; cash $108.0M.
UGN-103 NDA on track for Q3 2026; new patent allowance extends ZUSDURI protection to July 2044.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.